Delivering a Sleek 10-Minute Consultancy Presentation

This presentation addresses Daraga's challenges by focusing on offsetting revenue drops and emphasising impactful biotech IP acquisitions. Using a robust scoring framework, it evaluates clinical viability, market potential, and strategic alignment while mitigating risks. A detailed analysis of cases, including CRISPR, oncology drug pipelines, RNAi, and mRNA platforms, forms the basis of recommendations. The strategy prioritises scalable, low-risk solutions like oncology drugs and mRNA...